Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance Experts convened at the NCCN 2025 Annual Conference to discuss the rapidly evolving landscape of artificial intelligence (AI) in cancer care, focusing on governance, opportunities, and challenges.…

At #NCCN2025, experts dug into how AI is transforming cancer care from automating documentation to reshaping clinical trials and enabling remote monitoring. Oncology’s data intensity makes it a proving ground for what's next in health tech.
#AI #CancerCare

Optimizing Antiemetic Strategies Improves Patient Outcomes in Cancer Care - Oncology Nurse Advisor New evidence supports olanzapine-containing regimens as highly effective in preventing chemotherapy-induced nausea and vomiting.

Advancements in antiemetic strategies continue to shape oncology care, with evidence supporting olanzapine-containing regimens as highly effective in preventing chemotherapy-induced nausea and vomiting.

bit.ly/42Vc0rW

#CancerCare #NCCN2025

NCCN 2025 Annual Conference illustrates the critical impact of cancer research on improving lives The National Comprehensive Cancer Network (NCCN)—an alliance of leading cancer centers—celebrated 30 years of helping people with cancer to live better lives during the NCCN 2025 Annu...

Roswell Park showed up strong at #NCCN2025 💬

Dr. Mary Reid brought attention to a critical issue: smoking cessation in cancer care.

We’re proud to be part of the conversation shaping the future of oncology.

Learn more: www.eurekalert.org/news-release...

Many Cancer Patients Afraid of AI in Health Care, Survey Suggests Though 45% of patients said they could see the benefits of AI in health care, 44% said the idea of AI in health care settings scares them.

In a survey of more than 600 #cancer patients, 44% said the idea of using #AI in health care scares them. Results were presented at #NCCN2025. shorturl.at/QKJTc

We had a great time at the recent #NCCN2025 meeting, connecting with hematology experts, diving into the latest evidence-based guidelines, and exploring innovations that are shaping the future of cancer care. Thanks to everyone who stopped by our booth!

Risk of Second Primary Malignancies After ICI Treatment Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Patients with lung cancer or melanoma have an increased risk of second primary malignancies after ICI therapy, according to research presented at #NCCN2025 by Muntaser Al Zyoud of the University of Jordan. #lcsm #melsm shorturl.at/vfIG8

40-GEP Test Can Improve Risk Stratification in CSCC A 40-gene expression profile test can improve risk stratification for patients with CSCC, according to researchers.

A 40-GEP test can improve risk stratification for patients with CSCC, according to research presented at #NCCN2025 by Dr Shlomo Koyfman of @clevelandclinic.bsky.social. #skcsm shorturl.at/78Vpj

Our experts are always advancing cancer care!

Last week, they joined top centers at #NCCN2025 in Orlando to share research and drive progress for patients everywhere.

We're proud of our Roswell Park team! 💙

Biomarker Testing Is on the Rise, but Turnaround Time Has Not Improved Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

Biomarker testing in patients with advanced NSCLC has increased in recent years, but turnaround time for test results has remained roughly the same, according to research presented at #NCCN2025 by Dr Xiao Wang of @yalecancer.bsky.social. #lcsm shorturl.at/vcLjt

AYAs With Cancer Have Higher Risk of Financial Toxicity Than Other Cancer Patients AYA patients with cancer experience greater financial toxicity than cancer patients in other age groups, a large study suggests.

AYAs with cancer experience greater financial toxicity than cancer patients in other age groups, according to research presented at #NCCN2025 by Dr Brittany Kimball of @mayoclinic.org. #ayasm shorturl.at/zUAwS

High-Dose Chemo and HSCT May Provide Long-Term Benefits for MCL Patients High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

High-dose chemo and HSCT can provide long-term benefits in patients with MCL, according to research presented at #NCCN2025 by Dr Sandra Frimpong of @unmc.bsky.social. #lymsm shorturl.at/oL5Jl

Continuing With Pembrolizumab-Based Therapy Beyond Progression May Improve OS Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that treatment.

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that treatment, according to research presented at #NCCN2025 by Natalie Johns of OSUCCC. #lcsm shorturl.at/Y9QMw

Our Roswell Park experts are in Orlando for #NCCN2025! 🎉

Kicking off the event, Dr. Renuka Iyer shared insights on “Setting Up for Success: A How-To Guide for Life After Fellowship,” while Dr. Andrew Storer connected with attendees at our booth.

Stay tuned for more updates!

AYAs with cancer are more likely than other cancer patients to experience financial toxicity, according to research presented at #NCCN2025 by Dr Brittany Kimball of @mayoclinic.org. #ayasm

Patients with metastatic NSCLC who continue ICI therapy plus RT after progression have better survival than those who continue ICI therapy alone, according to research presented at #NCCN2025 by Natalie Johns of OSUCCC. #lcsm

For certain MCL patients, autoPSCT during first complete remission may produce long-term disease-free survival, according to Dr Sandra Frimpong of @unmc.bsky.social. She presented this research, from a landmark analysis, at #NCCN2025. #lymsm

For anyone attending #NCCN2025 in Orlando, I'm excited to be speaking during the immune checkpoint inhibitor toxicities session at 1 pm on Friday 3/28. Looking forward to talking about immune-mediated hepatitis with an oncology audience!

@ucsfcancer.bsky.social #LiverSky